The emergence of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to deliver significant improvements in fat loss compared to existing therapies. Early patient data have demonstrated marked reductions in body mass , conceivably markin